Merck & Co Inc (MRK): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Merck ( MRK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Merck rose 80 cents (1.9%) to $42.22 on average volume. Throughout the day, 13.2 million shares of Merck exchanged hands as compared to its average daily volume of 13.8 million shares. The stock ranged in a price between $41.58-$42.22 after having opened the day at $41.68 as compared to the previous trading day's close of $41.42. Other companies within the Health Care sector that increased today were: Novogen ( NVGN), up 209.6%, Rochester Medical Corporation ( ROCM), up 19%, Infinity Pharmaceuticals ( INFI), up 16.8%, and Five Star Quality Care Incorporated ( FVE), up 14.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Merck has a market cap of $125.92 billion and is part of the drugs industry. The company has a P/E ratio of 18.8, above the S&P 500 P/E ratio of 17.7. Shares are up 1.2% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Merck a buy, one analyst rates it a sell, and five rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, USMD Holdings ( USMD), down 12.6%, NeuroMetrix ( NUROD), down 12.4%, NeuroMetrix ( NURO), down 12.4%, and CombiMatrix Corporation ( CBMX), down 10.6%, were all laggards within the health care sector with Medtronic ( MDT) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.